Stock Monitor: Enzo Biochem Post Earnings Reporting

LONDON, UK / ACCESSWIRE / December 13, 2017 / Active-Investors issued a free report on Cancer Genetics, Inc. (NASDAQ: CGIX), which is readily accessible upon registration at www.active-investors.com/registration-sg/?symbol=CGIX as the Company's latest news hit the wire. On December 11, 2017, the Company announced results of a study indicating the potential value of being platform-agnostic and choosing the best diagnostic modality to evaluate an important molecular biomarker, PD-L1, in Diffuse Large B-Cell Lymphomas (DLBCL). The results were presented on December 10, 2017, at the 59th ASH Annual Meeting in Atlanta. Sign up now for our free research reports at:

www.active-investors.com/registration-sg

Active-Investors.com is currently working on the research report for Enzo Biochem, Inc. (NYSE: ENZ), which also belongs to the Healthcare sector as the Company Cancer Genetics. Do not miss out and become a member today for free to access this upcoming report at:

www.active-investors.com/registration-sg/?symbol=ENZ

Active-Investors.com is focused on giving you timely information and the inside line on companies that matter to you. This morning, Cancer Genetics most recent news is on our radar and we have decided to include it on our blog post. Today's free coverage is available at:

www.active-investors.com/registration-sg/?symbol=CGIX

RNA-ISH Appeared to be More Sensitive in Identifying Cases of PD-L1 Expression

The study compared performance of multiple antibody clones versus PD-L1, and the current standard diagnostic modality, immunohistochemistry (IHC), to an in-situ hybridization (ISH), using the RNAscope® approach to determine the expression of PD-L1 in DLBCL cells. There were differences in the two modalities that indicated that RNA-ISH may be the superior approach related to the identification of PD-L1. RNA-ISH appeared to be more sensitive, identifying cases of PD-L1 expression that were negative using IHC.

High PD-L1 expression identified by RNA-ISH, but not IHC, was highly correlated with non-germinal center B-cell subtype. The study demonstrates that choice and integration of diagnostic modalities can provide key additional information to assist oncologists to more accurately select therapeutic options for their patients.

RNA-ISH Generates Superior Information Compared to IHC

Panna Sharma, President and Chief Executive Officer (CEO) of Cancer Genetics, stated that this study demonstrates for a particular tumor type, DLBCL, that RNA-ISH generates superior information compared to IHC alone, which has been the standard for many years. Cancer Genetics would like to take this approach further to the benefit of the oncology community and the patients it treats. Sharma added that companies and laboratories in precision oncology should utilize the platform, or platforms, that generate the best-validated information to drive treatment.

Cancer Genetics Selected by eFFECTOR to Provide Biomarker Discovery and Development Services for Novel Oncology Drugs

In April 2017, Cancer Genetics was chosen by eFFECTOR Therapeutics, Inc., a biopharmaceutical Company developing selective translation regulators for the treatment of cancer, to provide clinical biomarker services for eFFECTOR's lead product candidate eFT508. Pursuant to the agreement, the two Companies are working together on eFFECTOR's strategies to implement studies aiding in biomarker discovery and development, allowing further optimization of the eFT508 development as a single agent and in drug combinations. The eFT508 has been granted the orphan drug designation by the US Food and Drug Administration (FDA) for the treatment of DLBCL.

About Diffuse Large B-Cell Lymphomas (DLBCL)

DLBCL is a cancer of B cells, a type of white blood cell responsible for producing antibodies. It is the most common type of non-Hodgkin lymphoma among adults, occurring primarily in older individuals, with a median age of diagnosis at approximately 70 years of age. It can also occur in children and young adults in rare cases. DLBCL is an aggressive tumor which can arise in virtually any part of the body.

About PD-L1

PD-1 is a checkpoint protein on T cells, the immune cells. It normally acts as a type of ?off switch' that helps keep the T cells from attacking other cells in the body. When PD-1 binds to PD-L1, a protein on some normal - and cancer - cells, PD-1 basically tells the T cell to leave the other cell alone. Some cancer cells have large amounts of PD-L1, which helps them evade immune attack. Monoclonal antibodies that target either PD-1 or PD-L1 can block this binding and boost the immune response against cancer cells.

Stock Performance Snapshot

December 12, 2017 - At Tuesday's closing bell, Cancer Genetics' stock ended the trading session flat at $1.85.

Volume traded for the day: 269.43 thousand shares, which was above the 3-month average volume of 168.16 thousand shares.

Stock performance in the last twelve-month period ? up 32.14%; and year-to-date - up 37.04%

After yesterday's close, Cancer Genetics' market cap was at $41.01 million.

The stock is part of the Healthcare sector, categorized under the Medical Laboratories & Research industry. This sector was up 0.3% at the end of the session.

Active-Investors:

Active-Investors (A-I) produces regular sponsored and non-sponsored reports, articles, stock market blogs, and popular investment newsletters covering equities listed on NYSE and NASDAQ and Canadian stocks. A-I has two distinct and independent departments. One department produces non-sponsored analyst certified content generally in the form of press releases, articles and reports covering equities listed on NYSE and NASDAQ and the other produces sponsored content (in most cases not reviewed by a registered analyst), which typically consists of compensated investment newsletters, articles and reports covering listed stocks and micro-caps. Such sponsored content is outside the scope of procedures detailed below.

A-I has not been compensated; directly or indirectly; for producing or publishing this document.

PRESS RELEASE PROCEDURES:

The non-sponsored content contained herein has been prepared by a writer (the "Author") and is fact checked and reviewed by a third-party research service company (the "Reviewer") represented by a credentialed financial analyst [for further information on analyst credentials, please email info@active-investors.com. Rohit Tuli, a CFA® charter-holder (the "Sponsor"), provides necessary guidance in preparing the document templates. The Reviewer has reviewed and revised the content, as necessary, based on publicly available information which is believed to be reliable. Content is researched, written and reviewed on a reasonable effort basis. The Reviewer has not performed any independent investigations or forensic audits to validate the information herein. The Reviewer has only independently reviewed the information provided by the Author according to the procedures outlined by A-I. A-I is not entitled to veto or interfere in the application of such procedures by the third-party research service company to the articles, documents or reports, as the case may be. Unless otherwise noted, any content outside of this document has no association with the Author or the Reviewer in any way.

NO WARRANTY

A-I, the Author, and the Reviewer are not responsible for any error which may be occasioned at the time of printing of this document or any error, mistake or shortcoming. No liability is accepted whatsoever for any direct, indirect or consequential loss arising from the use of this document. A-I, the Author, and the Reviewer expressly disclaim any fiduciary responsibility or liability for any consequences, financial or otherwise arising from any reliance placed on the information in this document. Additionally, A-I, the Author, and the Reviewer do not (1) guarantee the accuracy, timeliness, completeness or correct sequencing of the information, or (2) warrant any results from use of the information. The included information is subject to change without notice.

NOT AN OFFERING

This document is not intended as an offering, recommendation, or a solicitation of an offer to buy or sell the securities mentioned or discussed, and is to be used for informational purposes only. Please read all associated disclosures and disclaimers in full before investing. Neither A-I nor any party affiliated with us is a registered investment adviser or broker-dealer with any agency or in any jurisdiction whatsoever. To download our report(s), read our disclosures, or for more information, visit http://active-investors.com/legal-disclaimer/.

CONTACT

For any questions, inquiries, or comments reach out to us directly. If you're a company we are covering and wish to no longer feature on our coverage list contact us via email and/or phone between 09:30 EDT to 16:00 EDT from Monday to Friday at:

Email: info@active-investors.com

Phone number: 73 29 92 6381

Office Address: 6, Jalan Kia Peng, Kuala Lumpur, 50450 Kuala Lumpur, Wilayah Persekutuan Kuala Lumpur, Malaysia

CFA® and Chartered Financial Analyst® are registered trademarks owned by CFA Institute.

SOURCE: Active-Investors